Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.

Abstract excerpt

The bcr-abl chimeric gene is found in 95% of chronic myeloid leukemia (CML) patients and is thought to be seminal to the etiology of the disease. The possibility of using ribozymes to suppress bcr-abl gene expression and subsequently alter the malignant phenotype of hematopoietic cells may provide an alternative therapeutic approach to current regimens. A series of hammerhead ribozymes targeted to a b3a2 bcr-abl...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Fusion Proteins, bcr-abl
• Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive